CTMX Latest Headlines

CytomX Therapeutics’ $250 Million Equity Offering Strengthens Pipeline for Next-Generation Cancer Treatments

Market Chameleon (Wed, 18-Mar 7:06 AM)

CytomX's Varsetatug Masetecan Shows 32% Response Rate in Late-Line Colorectal Cancer—Phase 1 Data Highlights Emerging Potential

Market Chameleon (Mon, 16-Mar 9:53 AM)

CytomX’s 2025 Results Show Strong Financial Position as Pipeline Advances Toward Pivotal Data

Market Chameleon (Mon, 16-Mar 7:29 AM)

CytomX Schedules March 16, 2026 for Full-Year 2025 Results: Focus Sharpens on Pipeline Progress and Oncology Partnerships

Market Chameleon (Wed, 4-Mar 9:29 AM)

CytomX Therapeutics to Spotlight Novel Oncology Technologies at February Conferences

Market Chameleon (Wed, 4-Feb 8:54 AM)